Caroline Demangel received her PhD from the National Institute of Agronomy Paris-Grignon (INA-PG) in 1991. She worked as a post-doctoral fellow on the generation of phage-displayed libraries of antibodies at the Pasteur Institute (Paris), then at the Centenary Institute (Sydney) on the design of subunit vaccines targeting dendritic cells. Back in Paris in 2002, she joined the team of Stewart Cole to develop novel approaches to mycobacterial disease diagnosis and prevention. Since 2011, she’s been directing the “Immunobiology and Infection” Unit in the Immunology department of the Pasteur Institute. Research in her laboratory aims at understanding the mechanisms by which pathogenic mycobacteria escape from human immune responses. Currently, her work is focused on the role played by lipid factors uniquely produced by these bacteria that perturb central metabolic pathways in immune cells. The long term goal of these studies is to find novel ways to treat mycobacterial infections, and more generally to manipulate the immune system through metabolism.
Think tank: Metabolism
We are pleased to announce the next Microbes, Immunity and Metabolism international conference www.metamim-2017.org , to be held in Paris at the Institut Pasteur on November 15th-17th, 2017. Recent studies highlight the extensive metabolic […]
Therapeutic potential of mycolactone surrogates
Inflammation adversely affects the health of millions of people worldwide and there is an unmet medical need for better anti-inflammatory drugs. Our group evaluates the therapeutic interest of mycolactone, a polyketide-derived macrolide produced by […]
Mycolactone of M. ulcerans and immunodulation
Mycolactone is a diffusible macrolide produced by Mycobacterium ulcerans, the causative agent of a chronic skin disease called Buruli ulcer. Defective cellular immune responses, at the local and systemic levels, are hallmarks of Buruli […]
Biomarkers of Buruli ulcer disease
Buruli ulcer is the third most common mycobacterial disease after Tuberculosis and Leprosy. It is a chronic, necrotizing disease of the skin and soft tissues that is reported in over thirty tropical and subtropical […]
Mycobacterial phenolic glycolipids and innate host defenses
Across different species of mycobacteria, phenolic glycolipids (PGL) share a common lipid core and phenol ring that are embedded in the cell envelope, and differ in the saccharidic portion that is exposed on the […]
Mycolactone of M. ulcerans and the actin cytoskeleton
A distinctive feature of the human pathogen Mycobacterium ulcerans is the production of mycolactone. This original polyketide-derived macrolide is essential for bacterial virulence and sufficient to induce ulcerative lesions in the skin that are […]
2017Mycolactone displays anti-inflammatory effects on the nervous system, PLoS Negl Trop Dis 2017 Nov;11(11):e0006058.
2017Modular total syntheses of mycolactone A/B and its [(2)H]-isotopologue, Org. Biomol. Chem. 2017 Sep;15(36):7518-7522.
2017Sec61 blockade by mycolactone inhibits antigen cross-presentation independently of endosome-to-cytosol export, Proc. Natl. Acad. Sci. U.S.A. 2017 Jul;114(29):E5910-E5919.
2017Zika virus induces massive cytoplasmic vacuolization and paraptosis-like death in infected cells, EMBO J. 2017 Jun;36(12):1653-1668.
2017Pathogenic and immunosuppressive properties of mycobacterial phenolic glycolipids, Biochimie 2017 Mar;.
2016Mycolactone subverts immunity by selectively blocking the Sec61 translocon, J. Exp. Med. 2016 Dec;213(13):2885-2896.
2016Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Induced Immune Responses, Cell Rep 2016 09;16(10):2777-2791.
2015Metabolomic profiles delineate mycolactone signature in Buruli ulcer disease, Sci Rep 2015;5:17693.
2015Shaping mycolactone for therapeutic use against inflammatory disorders, Sci Transl Med 2015 May;7(289):289ra85.
2014Synthetic variants of mycolactone bind and activate Wiskott-Aldrich syndrome proteins, J. Med. Chem. 2014 Sep;57(17):7382-95.
+View full list of publications